A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer

A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer

Enzalutamide (ENZ) is a second-generation androgen receptor (AR) antagonist used for the treatment of castration-resistant prostate cancer (CRPC) and reportedly prolongs survival time within a year of starting therapy. However, CRPC patients can develop ENZ resistance (ENZR), mainly driven by abnorm...

Full description

Bibliographic Details
Main Authors: Yan Li, Ya Chu, Guangjiang Shi, Xiaobin Wang, Wanli Ye, Chun Shan, Dajia Wang, Di Zhang, Wei He, Jingwei Jiang, Shuqian Ma, Yuhong Han, Zhili Zhao, Shijia Du, Zhen Chen, Zhiyu Li, Yong Yang, Chen Wang, Xi Xu, Hongxi Wu
Format: Article
Language:English
Published: Elsevier 2022-11-01
Series:Acta Pharmaceutica Sinica B
Subjects:
Drug resistance
Enzalutamide
Castration-resistant prostate cancer
Androgen receptor splice variant 7
Heterodimers
Degradation
Online Access:http://www.sciencedirect.com/science/article/pii/S2211383522002106

Internet

http://www.sciencedirect.com/science/article/pii/S2211383522002106

Similar Items